Company: MDCXW
Filing Date: 2025-06-30
Form Type: DEF 14A
Source: 0001062993-25-012273
Chunk: 35

Company: Medicus Pharma Ltd.
Filing Date: 2025-06-30
Form: DEF 14A
Chunk 35
---
 or classes respectively (if there is more than one class of shares outstanding for the time being). Notwithstanding the foregoing, if the Company has only one shareholder, or only one shareholder of any class or series of shares, the shareholder present in person or by proxy constitutes a meeting and a quorum for such meeting.

In accordance with Section 116(2) of the OBCA, the Quorum Amendment is hereby submitted for confirmation by the Shareholders of the Company.

The Board recommends that Shareholders vote in favor of the following by-law resolution at the Meeting (the "By-Law Resolution").

"RESOLVED, as an ordinary resolution of the shareholders of Medicus Pharma Ltd., that:

(a)the amendment of By-Law No. 1, such that Article 3.2 of By-Law No. 1 is in the form attached hereto as Schedule "A", is hereby confirmed, ratified and approved;

(b)any director or officer of the Company be and he or she is hereby authorized and directed, for and on behalf of the Company, to execute and deliver all such documents and to do all such other acts or things as he or she may determine to be necessary or advisable to give effect to this resolution, the execution of any such document or the doing of any such other act or thing being conclusive evidence of such determination."

In order to pass the By-Law Resolution, at least a majority of the votes cast by the Shareholders present at the Meeting in person or by proxy must be voted in favor of the By-Law Resolution. If the By-Law Resolution does not receive the requisite shareholder approval, the previous By-Law No. 1, which provided for a 10% quorum requirement at meetings of Shareholders, will be reinstated.

THE BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE "" THE QUORUM AMENDMENT IN PROPOSAL 3.

<div align='center'>- 29 -

PROPOSAL 4 - ISSUANCE OF SHARES UNDER NASDAQ 20% RULE</div>

Under Nasdaq Rule 5635(d) (the "Nasdaq 20% Rule"), a Nasdaq-listed company must obtain shareholder approval prior to issuing (or potentially issuing) common share (or securities convertible into or exercisable for common share) in a transaction, other than a public offering as defined under Nasdaq Rules, if the issuance equals 20% or more of the company's outstanding common shares (or 20% or